BTRC and plasma cell myeloma: Because genetic inhibition of both β-TrCP paralogs in mice does not result in an overt phenotype beyond reversible testicular pathology [19], targeting β-TrCP in myeloma patients is unlikely to be associated with significant side effects and offers a viable alternative to general proteasome inhibitors.